Cite
HARVARD Citation
Sum, E. et al. (2022). The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation. Journal for immunotherapy of cancer. 10 (3), p. . [Online].